- Home
- VIVS vs GLTO Comparison
VIVS vs GLTO Comparison
Compare VIVS & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- GLTO
- Stock Information
- Founded
- VIVS 2007
- GLTO 2011
- Country
- VIVS United States
- GLTO Denmark
- Employees
- VIVS N/A
- GLTO N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- GLTO Health Care
- Exchange
- VIVS Nasdaq
- GLTO Nasdaq
- Market Cap
- VIVS 3.6M
- GLTO 4.0M
- IPO Year
- VIVS N/A
- GLTO 2020
- Fundamental
- Price
- VIVS $1.80
- GLTO $3.07
- Analyst Decision
- VIVS
- GLTO Buy
- Analyst Count
- VIVS 0
- GLTO 1
- Target Price
- VIVS N/A
- GLTO $10.00
- AVG Volume (30 Days)
- VIVS 137.3K
- GLTO 82.7K
- Earning Date
- VIVS 06-06-2025
- GLTO 05-08-2025
- Dividend Yield
- VIVS N/A
- GLTO N/A
- EPS Growth
- VIVS N/A
- GLTO N/A
- EPS
- VIVS N/A
- GLTO N/A
- Revenue
- VIVS $122,000.00
- GLTO N/A
- Revenue This Year
- VIVS $59.08
- GLTO N/A
- Revenue Next Year
- VIVS $18.24
- GLTO N/A
- P/E Ratio
- VIVS N/A
- GLTO N/A
- Revenue Growth
- VIVS N/A
- GLTO N/A
- 52 Week Low
- VIVS $1.56
- GLTO $2.01
- 52 Week High
- VIVS $21.96
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- GLTO 53.39
- Support Level
- VIVS N/A
- GLTO $2.92
- Resistance Level
- VIVS N/A
- GLTO $3.38
- Average True Range (ATR)
- VIVS 0.00
- GLTO 0.25
- MACD
- VIVS 0.00
- GLTO 0.04
- Stochastic Oscillator
- VIVS 0.00
- GLTO 57.53
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.